Hemostatic changes in patients with end stage renal disease undergoing hemodialysis

被引：38
作者：
Alves Rios, Danyelle Romana [1 ]
Carvalho, Maria das Gracas [1 ]
Lwaleed, Bashir A. [1 ]
Simoes e Silva, Ana Cristina [1 ]
Gomes Borges, Karina Braga [1 ]
SantAna Dusse, Luci Maria [1 ]
机构：
[1] Univ Fed Minas Gerais, Fac Farm, Clin & Toxicol Anal Dept, BR-31270901 Belo Horizonte, MG, Brazil
来源：
CLINICA CHIMICA ACTA | 2010年 / 411卷 / 3-4期
关键词：
Hemodialysis; Coagulation; Fibrinolysis; Platelets; End stage renal disease; VASCULAR ACCESS THROMBOSIS; FACTOR PATHWAY INHIBITOR; ENDOTHELIAL-CELL MARKERS; GLYCOPROTEIN-IIB-IIIA; UREMIC PATIENTS; ARTERIOVENOUS-FISTULA; PLATELET-AGGREGATION; TISSUE FACTOR; MAINTENANCE HEMODIALYSIS; GUANIDINOSUCCINIC ACID;
D O I：
10.1016/j.cca.2009.11.022
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
Patients undergoing hemodialysis may show both thrombotic complications and bleeding abnormalities. Hemostatic changes in patients on hemodialysis may result from alterations in vessel wall integrity and platelet function, and reduced blood flow in the native arteriovenous fistula. Vascular complications represent 20-25% of all hospitalizations of patients on hemodialysis. Literature survey revealed that changes in the hemostatic system may play a major role in vascular complications observed in these patients. Thus, it is essential to investigate hemostatic alterations in patients on hemodialysis so that adequate regimes for anticoagulant therapy could be implemented. In this review we discuss hemostatic abnormalities in end stage renal disease patients undergoing hemodialysis. (c) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码：135 / 139
页数：5
相关论文
共 78 条
  • [1] Predictors of vascular access thrombosis among patients on the cadaveric renal transplantation waiting list
    Akman, B
    Afsar, B
    Ataç, FB
    Ibis, A
    Arat, Z
    Sezer, S
    Ozdemir, FN
    Haberal, M
    [J]. TRANSPLANTATION PROCEEDINGS, 2006, 38 (02) : 413 - 415
  • [2] Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation
    Ambuhl, PM
    Wuthrich, RP
    Korte, W
    Schmid, L
    Krapf, R
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (11) : 2355 - 2364
  • [3] Role of genetic mutations in vascular access thrombosis among hemodialysis patients waiting for renal transplantation
    Ataç, B
    Yakupoglu, Ü
    Özbek, N
    Özdemir, FN
    Bilgin, N
    [J]. TRANSPLANTATION PROCEEDINGS, 2002, 34 (06) : 2030 - 2032
  • [4] Deviations in coagulation activation due to treatment with different haemodialysis membranes
    Bartels, PCM
    Schoorl, M
    Schoorl, M
    Nubé, MJ
    [J]. SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2003, 63 (06) : 417 - 424
  • [5] INHIBITION OF PLATELET-FUNCTION BY UREMIC MIDDLE MOLECULES
    BAZILINSKI, N
    SHAYKH, M
    DUNEA, G
    MAMDANI, B
    PATEL, A
    CZAPEK, E
    AHMED, S
    [J]. NEPHRON, 1985, 40 (04): : 423 - 428
  • [6] The role of intrinsic fibrinolytic system activation in pathogenesis of hemostasis disturbances in hemodialyzed patients with chronic renal failure
    Bronisz, M
    Rosc, D
    Bronisz, A
    Manitius, J
    Nartowicz, E
    [J]. RENAL FAILURE, 2004, 26 (03) : 223 - 229
  • [7] CASES A, 1993, KIDNEY INT, V43, pS217
  • [8] CASTALDI PA, 1966, LANCET, V2, P66
  • [9] Tissue factor pathway inhibitor (TFPI) activity in uremic patients during hemodialysis
    Cella, G
    Vertolli, U
    Naso, A
    Vianello, A
    Rampin, E
    Sbarai, A
    Boeri, G
    Strauss, WE
    [J]. THROMBOSIS RESEARCH, 1996, 81 (06) : 671 - 677
  • [10] Significance of platelet activation in vascular access survival of haemodialysis patients
    Chuang, YC
    Chen, JB
    Yang, LC
    Ku, CY
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (05) : 947 - 954
12345678